AffyImmune Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AffyImmune Therapeutics Inc. - overview
Established
2016
Location
Natick, MA, US
Primary Industry
Biotechnology
About
AffyImmune Therapeutics Inc. focuses on developing innovative cellular therapies that leverage the patient's immune system to target tumor cells overexpressing ICAM-1, with an emphasis on treating advanced thyroid cancers. Founded in 2016 and based in Natick, US, AffyImmune Therapeutics Inc. specializes in immunotherapy.
The firm has raised a total of USD 30. 00 mn in its Series A funding round led by ORI Capital on October 7, 2021, with a focus on developing ICAM-1-directed therapies. Founders Gang Song and Moonsoo Jin have a history of involvement in innovative healthcare solutions. AffyImmune Therapeutics, Inc.
specializes in developing advanced cellular therapies that utilize the patient’s immune system to target and eliminate tumor cells characterized by the overexpression of ICAM-1. Their primary product, AIC100, is an ICAM-1-directed CAR T therapy aimed specifically at patients suffering from anaplastic and advanced differentiated thyroid cancers. The innovative technology enhances CAR T cell affinity, allowing for the selective destruction of tumor cells while preserving healthy tissue. The company also ensures non-invasive monitoring of engineered CAR T cells during treatment, addressing significant unmet medical needs in oncology, particularly in North America and Europe.
AffyImmune Therapeutics, Inc. has a revenue model that relies on partnerships and collaborations with healthcare providers and research institutions. These agreements typically involve the provision of CAR T cell therapies, especially AIC100, to oncologists and hospitals treating advanced thyroid cancers. Revenue is generated through research funding, licensing agreements, and milestone payments linked to the clinical development and commercialization of their therapies, reflecting the innovative nature of their solutions.
AffyImmune Therapeutics Inc. is utilizing the USD 30. 00 mn raised in Series A funding to further advance the Phase 1 study of AIC1000, which is targeted for treating anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer. The company aims to expand its therapeutic offerings and improve patient outcomes through innovative products, while also exploring new markets for their therapies in regions with high incidences of thyroid cancer.
Plans include strategic collaborations and research initiatives to facilitate this growth.
Current Investors
ORI Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.affyimmune.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.